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Abstract
Introduction Complete resolution of hypertension after adrenalectomy for primary aldosteronism is far from a
certainty. This stresses the importance of adequate preoperative patient counseling. The aldosteronoma resolution
score (ARS) is a simple and easy to use prediction model only including four variables: B 2 antihypertensive
medications, body mass index B 25 kg/m2, duration of hypertension B 6 years and female sex. However, because
the model was developed and validated within the USA over a decade ago, the applicability in modern practice and
outside of the USA is questionable. Therefore, we aimed to validate the ARS in current clinical practice within an
international cohort.
Materials and method Patients who underwent unilateral adrenalectomy, between 2010 and 2016, in 16 medical
centers from the USA, Europe (EU), Canada (CA) and Australia (AU) were included. Resolution of hypertension was
defined as normotension without antihypertensive medications.
Results In total, 514 patients underwent adrenalectomy and 435 (85%) patients were eligible. Resolution of
hypertension was achieved in 27% patients within the total cohort and in 22%, 30%, 40% and 38% of patients within
USA, EU, CA and AU, respectively (p = 0.015). The area under the curve (AUC) for the complete cohort was 0.751.
Geographic validation displayed a AUC within the USA, EU, CA and AU of 0.782, 0.681, 0.811 and 0.667,
respectively.
Discussion The ARS is an easy to use prediction model with a moderate to good predictive performance within
current clinical practice. The model showed the highest predictive performance within North America but potentially
has less predictive performance in EU and AU.
Introduction
Primary aldosteronism (PA) is the most common form of
secondary hypertension with an estimated prevalence
between 5 and 20% depending on the severity of hyper-
tension [1–4]. PA leads to morbidity and mortality through
the effects of hypertension and aldosteronism itself on
critical organs [5–8]. Therefore, the ultimate goal of
treatment is resolution of both. Bilateral adrenal hyper-
plasia is treated medically while patients with an unilateral
aldosterone-producing adenoma (APA) are preferably
treated by unilateral adrenalectomy [9–12].
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Cure of aldosteronism is reported in the majority of
patients after adrenalectomy for APA [13–15]. However,
resolution of hypertension, also called cure of hypertension
(i.e., a normotensive patient without antihypertensive
medications), is far from a certainty. In the past, resolution
rates were estimated around 50% [13, 14, 16]. However,
recently Williams et al. [15] showed less optimistic results
by presenting a 37% resolution rate within a large, inter-
national and well-executed study. Moreover, recently our
own study group also published on blood pressure-related
outcomes after surgery for PA and we presented an even
lower resolution rate of 27–30% [17, 18]. This stresses the
importance of adequate patient counseling and expectation
management before performing an operation. To do this,
clinicians need a user-friendly and reliable prediction
model.
In 2008, Zarnegar et al. [19] proposed the Aldos-
teronoma Resolution Score (ARS) as a practical prediction
model for resolution of hypertension. The model is very
easy to use because it only includes four dichotomous
preoperative patient/disease characteristics associated with
a high probability of resolution of hypertension: taking B 2
number of antihypertensive medications (AHTN) (2
points), body mass index (BMI) B 25 kg/m2 (1 point),
duration of hypertension B 6 years (1 point) and female
sex (1 point). Based on the combined scores, three likeli-
hood ratios for resolution of hypertension were identified:
low (0–1), medium (2–3) and high (4–5) with corre-
sponding likelihoods of resolution of 28%, 46% and 75%,
respectively. The area under the curve (AUC) was 0.913
[19].
In the past, validation of the ARS showed contradicting
results between studies and was frequently performed
within small and single country or single-center study
populations. In addition, these studies often included
patients treated over several decades due to the low inci-
dence of disease. Furthermore, the ARS was developed
over a decade ago and, because of the improvement of
diagnostic modalities and guidelines, patient care has made
substantial progress over the years. This underscores the
need to evaluate the clinical applicability and usefulness of
the ARS in the current clinical APA population, especially
because the performance of a prediction model may change
over time [20–22]. In addition, since the prediction model
was developed within the USA, the ARS is likely to have
lower predictive value outside of the USA which questions
the generalizability of the ARS worldwide. Therefore, we
aimed to be the first to validate the ARS in current clinical
practice and expand this geographically in a worldwide
cohort of patients who had adrenalectomy between 2010
and 2016.
Methods
Patients and data collection
We performed a retrospective cohort study across 16
medical centers in the USA, Europe (EU), Canada (CA)
and Australia (AU) (Fig. 1). Derivation of this cohort has
been described before [17]. In brief, all patients who
underwent unilateral adrenalectomy between 2010 and
2016 for APA were included. Because we aimed to make
our study representative for current real-life clinical prac-
tice no strict inclusion or exclusion criteria were used
regarding screening, case confirmation or subtype testing.
Laterality of disease was based on computerized tomog-
raphy (CT) and/or magnetic resonance imaging (MRI) and/
or adrenal venous sampling (AVS). In general, biochemical
evidence for PA was based on an elevated aldosterone-to-
renin ratio (ARR) indicating PA. Patients with missing
preoperative or follow-up data regarding systolic blood
pressure (SBP), diastolic blood pressure (DBP) or corre-
sponding number of AHTN were excluded (Fig. 1). Insti-
tutional review board approval was obtained in all
participating centers.
Definitions and outcomes
Resolution of hypertension was defined as a postoperative
normotensive patient (i.e., SBP\ 140 mmHg and
DBP\ 90 mmHg) without antihypertensive medications.
Office blood pressure measurements were performed dur-
ing outpatient visitation. Number of AHTN was defined as
the number of different antihypertensive medications used.
The defined daily dose (DDD) was calculated with the
World Health Organization Anatomical Therapeutic
Chemical/DDD Index 2017 (see https://www.whocc.no/
atc_ddd_index/). When a medication stop was performed
due to laboratory measurements, for example prior to the
ARR, the number of AHTN, DDD and corresponding
blood pressure before discontinuation were used. Bio-
chemical data were classified as elevated/suppressed when
values were above/below the local reference range.
Hypokalemia was defined as either a potassium level below
the local reference ranges or the use of potassium supple-
mentation. The predictive accuracy of the ARS was
reported as the proportion of patients with resolution for
every ARS subgroup. Geographic validation was per-
formed after division of the cohort into four geographic
regions: USA, EU, CA and AU [20–22]. The goal was to
assess resolution of hypertension at follow-up closest to
6 months after adrenalectomy.
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Statistical analysis
The Chi-Square test and Fisher’s exact test were used to
analyze group differences for categorical variables. For
comparisons of continuous variables between multiple
groups, one-way ANOVA was used for normally dis-
tributed data and Kruskal–Wallis Test for not normally
distributed data. A p value of\ 0.05 was considered sta-
tistically significant. Multiple variables used as predictors
in the ARS had missing values. To be able to calculate the
ARS in all patients, these variables were imputed using
multiple imputation with 20 imputed datasets [23]. The
duration of hypertension and BMI was missing in 16% and
8% of patients, respectively. Gender and number of AHTN
were known in all patients (Table 1). The primary endpoint
of this study (i.e., resolution of hypertension) was known in
all patients. Pooled negative predictive values (NPV),
positive predictive values (PPV) and AUCs of the ARS for
resolution were calculated. Statistical analysis was per-
formed using SPSS version 25.0 (IBM Corp, New York,
USA), and figures were constructed using Graphpad Prism
version 7.02 (GraphPad Software Inc, California, USA).
Results
Baseline characteristics are shown in Table 1. Five hun-
dred fourteen patients underwent adrenalectomy and 435
(85%) patients were eligible for analysis. Two hundred
forty-eight (57%), 106 (24%), 42 (10%) and 39 (9%)
patients were included from USA, EU, CA and AU,
respectively. Patients within the USA had a BMI of
30.4 ± 6.7, which was significantly higher compared to
patients from the EU, CA or AU. The other predictors used
within the ARS were comparable between the different
regions. Furthermore, CT and AVS were performed in 88%
and 64% of patients and the use of these modalities was
comparable between the regions. A confirmatory test was
more frequently performed within EU and AU compared to
the USA and CA, 56% and 46% versus 27% and 17%,
Fig. 1 Flowchart of included patients
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Table 1 Baseline characteristics of the complete cohort and stratified by region
Variable All patients
(n = 435)
USA (n = 248)
(57%)
Europe
(n = 106) (24%)
Canada
(n = 42) (10%)
Australia













Age at surgery (years) 50.7 ± 11.4 50.0 ± 11.6 51.3 ± 10.3 52.5 ± 11.6 51.2 ± 12.4 0.485
Female 186 (43%) 113 (46%) 37 (35%) 19 (45%) 17 (44%) 0.310
Duration of HTN (years)
(n = 366)*
9 (0–42) 10 (0–42) 9 (1–33) 7 (1–40) 6 (0–30) 0.220
Body mass index
(n = 402)
29.7 ± 6.1 30.4 ± 6.7 28.9 ± 5.1 28.9 ± 4.6 27.5 ± 4.7 0.032
No. AHTN* 3 (0–8) 3 (0–8) 3 (0–7) 3 (1–6) 3 (0–5) 0.598
DDD (n = 405)* 3.7 (0.0–25.3) 3.7 (0.0–25.3) 3.5 (0.0–13.7) 3.9 (1.0–11.0) 2.2 (0.0–8.7) 0.290
Preoperative mean SBP
(mmHg)
150 ± 20 151 ± 20 154 ± 19 140 ± 17 149 ± 15 0.002
Preoperative mean DBP
(mmHg)
90 ± 13 89 ± 14 92 ± 12 87 ± 9 91 ± 12 0.150
Hypokalemia (n = 429) 317 (74%) 185 (76%) 77 (73%) 29 (69%) 26 (67%) 0.481
Elevated aldosterone level
(n = 408)
225 (55%) 124 (52%) 56 (57%) 23 (58%) 22 (69%) 0.316
Suppressed renin level/
activity (n = 370)
245 (66%) 138 (64%) 60 (70%) 31 (86%) 16 (52%) 0.015
ARR indicating PA
(n = 361)
341 (95%) 202 (93%) 74 (96%) 36 (100%) 29 (94%) 0.342
Elevated creatinine level
(n = 392)
71 (18%) 39 (19%) 19 (18%) 7 (17%) 6 (15%) 0.956
CT performed (n = 432) 378 (88%) 214 (87%) 89 (84%) 37 (88%) 38 (97%) 0.191
AVS performed (n = 434) 278 (64%) 160 (65%) 59 (56%) 28 (67%) 31 (80%) 0.187
MRI performed (n = 434) 72 (17%) 47 (19%) 16 (15%) 4 (10%) 5 (13%) 0.369
Confirmatory test
performed
143 (33%) 38 (27%) 80 (56%) 7 (17%) 18 (46%) <0.001
Surgical procedure <0.001
EPRA 171 (39%) 79 (32%) 44 (42%) 27 (64%) 21 (54%)
ELRA 65 (15%) 55 (22%) 8 (8%) 0 (0%) 2 (5%)
LTA 198 (46%) 113 (46%) 54 (51%) 15 (36%) 16 (41%)
Open 1 (\ 1%) 1 (\ 1%) 0 (0%) 0 (0%) 0 (0%)
Tumor laterality 0.916
Left 260 (60%) 149 (60%) 64 (60%) 23 (55%) 24 (62%)
Right 175 (40%) 99 (40%) 42 (40%) 19 (45%) 15 (38%)
Histology (n = 434) 0.058
Adenoma 362 (84%) 209 (85%) 80 (76%) 39 (93%) 34 (87%)
Hyperplasia 58 (13%) 34 (14%) 20 (19%) 1 (2%) 3 (8%)
Adenoma/hyperplasia 13 (3%) 4 (2%) 5 (5%) 2 (5%) 2 (5%)
Follow-up after surgery <0.001
\ 1 month 101 (23%) 95 (38%) 3 (3%) 3 (7%) 0 (0%)
1–\ 3 months 39 (9%) 19 (8%) 11 (10%) 9 (21%) 0 (0%)
3–9 months 278 (64%) 131 (53%) 81 (76%) 27 (64%) 39 (100%)
[ 9–18 months 17 (4%) 3 (1%) 11 (10%) 3 (7%) 0 (0%)
*Values not normally distributed given as medians (range)
HTN hypertension, No. AHTN number of antihypertensive medications, SBP systolic blood pressure, DBP diastolic blood pressure, ARR
aldosterone-to-renin ratio, PA primary aldosteronism, CT computerized tomography, AVS adrenal venous sampling, MRI magnetic resonance
imaging, EPRA endoscopic posterior retroperitoneal adrenalectomy, ELRA endoscopic lateral retroperitoneal adrenalectomy, LTA laparoscopic
transabdominal adrenalectomy
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respectively. In 64% of patients, follow-up was performed
approximately 6 months after surgery (range 3–9 months).
Resolution of hypertension was achieved in 118 (27%)
patients within the total cohort and in 54 (22%), 32 (30%),
17 (40%) and 15 (38%) patients within USA, EU, CA and
AU, respectively (p = 0.015). No differences in resolution
rates were found between the centers within each of the
four regions (Fig. 2). Patients with and without preopera-
tive AVS achieved resolution of hypertension in 31% and
28%, respectively (p = 0.524). No significant differences
were seen between patients with and without a confirma-
tory test (p = 0.232). The rates of resolution of hyperten-
sion were comparable between the four follow-up periods
(p = 0.442) (Fig. 3) and between patients with\ 1 month
and 3–9 months follow-up (p = 0.400). Postoperative
potassium and aldosterone were measured in 95% and 64%
of patients, showing hypokalemia and hyperaldosteronism
in 12% and 4%, respectively. Biochemical outcomes
stratified per region are presented in supplement 1.
Validation of the ARS in current clinical practice
There were no significant differences in the dichotomous
ARS variables between the geographic regions (Table 2).
ARS 0, 1, 2, 3, 4 and 5 were observed in 25%, 19%, 20%,
20%, 10% and 6% of patients, respectively (Table 3).
These scores were comparable between the four regions
(p = 0.484). Within the complete cohort, assessment of the
proportion of patients with resolution of HTN within each
ARS showed a likelihood of 7% in case of ARS 0 and 84%
in case of ARS 5. This corresponded to a NPV of 93% for
ARS 0 and a PPV of 84% for ARS 5. The corresponding
AUC was 0.751 (95% CI 0.699–0.802). When using the
likelihood levels as proposed by Zarnegar et al. [19] ARS
0–1 (low), ARS 2–3 (medium) and ARS 4–5 (high) showed
predictive accuracies of 11, 33 and 59%, respectively. The
corresponding AUC for this categorical ARS was 0.718
(95% CI 0.664–0.772). Geographic validation showed a
NPV of 96% for ARS 0 and a PPV of 79% for ARS 5 with
a AUC of 0.782 (95% CI 0.714–0.851) within the USA. In
EU, a NPV of 88%, PPV of 75% and AUC of 0.681 (95%
CI 0.571–0.792) were observed. Furthermore, a NPV, PPV
and AUC of 90%, 100% and 0.811 (95% CI 0.678–0.943)
and 60%, 67% and 0.667 (95% CI 0.483–0.851) were
found for CA and AU, respectively.
Discussion
This study validated the ARS within a worldwide cohort of
patients which is representative for current clinical prac-
tice. Validation of the ARS within the complete cohort
showed a moderate to good AUC of 0.751. Furthermore,
the AUC was 0.782 within current US APA population.
Although this prognostic accuracy was lower compared to
the original data presented by Zarnegar et al. (AUC 0.913),
it could still be considered as moderate to good prognostic
performance [19]. Further geographic validation of the
ARS displayed a comparable prognostic value within CA
(AUC 0.811), but lower prognostic performance within EU
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Fig. 2 Rates of resolution of hypertension stratified by region and medical center
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(AUC 0.681) and AU (AUC 0.667) potentially indicating
limited generalizability of the ARS outside the North
American population.
The ARS, as introduced in 2008 by Zarnegar et al., is a
user-friendly model to predict the likelihood of resolution
of hypertension after adrenalectomy for PA [19]. Because
the ARS was developed in the USA within a single-center
cohort of 100 patients over a decade ago, it is essential to
confirm that the model also predicts well in, and thus is
generalizable to, APA patients which were treated within
other institutions or in different clinical settings and diag-
nostic protocols [20–22]. This underscores the need for the
evaluation of clinical applicability and usefulness of the
ARS in the current clinical APA population, especially
because the performance of a prediction model may change
over time [20–22]. In the past, validation of the prediction
model by others showed contradicting results; however,
these studies were single center or country and frequently
had small sample size [24–26]. Therefore, we chose to
perform validation of the ARS within our large and
worldwide cohort of patients, which at this time is the best
available population to truly evaluate the generalizability
in current real-life clinical practice. The results showed a
lower, but still moderate to good, predictive performance
of the ARS within the USA (AUC 0.782) compared to the
development dataset AUC 0.913 [19]. Usually, this is
expected because prediction models are likely to show
optimistic results within the development dataset, because
all development techniques are prone to produce ‘‘overfit-
ted’’ models, especially when small datasets (with limited
numbers of outcomes) are used [20–22]. In line, perfor-
mance is often poorer in validation studies because of
differences in case mix and domains. Because our study
contained almost 250 patients from the USA from seven
different medical centers, we believe this study shows a
good generalizability of the ARS within the USA. Fur-
thermore, results also showed a decent performance within
CA (AUC 0.811). Therefore, these results indicate that the
ARS could be an easy to use tool for clinicians from North
America to use during patient counseling. Nevertheless,
results showed a lower predictive performance of the ARS
within the EU (AUC 0.681) and AU (AUC 0.667)
demonstrating the potential limited transportability of the
model to other countries or continents worldwide.
Although this is potentially due to differences in case mix
and baseline characteristics, our results surprisingly
0 20 40 60 80 10
0
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Fig. 3 Rates of resolution of
hypertension stratified by
duration of follow-up
Table 2 Dichotomous variables used for the ARS stratified by region
Variables All patients
(n = 435)













Number (%) Number (%) Number (%) Number (%) Number (%)
No. antihypertensive
medications B 2
180 (41%) 97 (39%) 49 (46%) 19 (45%) 15 (39%) 0.584
Body mass index B 25 kg/m2* 98 (23%) 57 (23%) 20 (19%) 11 (26%) 10 (26%) 0.603
Duration of HTN B 6 years* 171 (39%) 91 (37%) 44 (42%) 18 (43%) 18 (46%) 0.499
Female 186 (43%) 113 (46%) 37 (35%) 19 (45%) 17 (44%) 0.310
*Including imputed data
No. number of, HTN hypertension
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showed no clear differences within the four predictors used
for the ARS or individual ARSs between the four regions.
For instance, although patients from the USA had signifi-
cant higher BMI compared to the other regions, this did not
result in a lower proportion of patients with BMI B 25 kg/
m2 or more patients with a low ARS (Table 2).
We observed resolution of HTN in 27% of patients
which is lower compared to the 42%, 50% and 52% pre-
sented in reviews or meta-analyses and the 37% presented
within another worldwide study by Williams et al. [13–16].
Most likely, this difference is multifactorial. For instance,
these earlier studies included patients treated over several
decades ago and therefore the lower rates of resolution
could be influenced by the worldwide increase in obesity
and background/not PA-related hypertension over the years
[27–29]. Furthermore, because we meant our results to be
representative for current clinical practice the preoperative
workup, including screening, case confirmation and sub-
type testing, was not as stringent as in other studies.
Potentially this led to less favorable outcomes compared to
studies only including patients who, for instance, under-
went AVS and thus represent more selected study popu-
lations. Although our results showed no difference in
resolution rates between patients with and without preop-
erative AVS, we cannot rule out that AVS truly does not
improve outcomes because our cohort and study design are
subject to confounding by indication. Further blood pres-
sure-related outcomes and the potential benefits of surgery
for patients without resolution of hypertension (i.e.,
reduction in blood pressure and antihypertensive medica-
tions) within this cohort were described in detail before
[17, 18].
When comparing rates of resolution between the four
regions, results showed a significantly lower resolution rate
within the USA (22%) compared to EU (30%), CA (40%)
and AU (38%). Besides a significantly higher mean BMI
within the USA, another potential influence on the lower
resolution rate could be the difference in preoperative
workup. While CT and AVS were performed just as often
within the four regions, a confirmatory test was performed
in only 27% of patients within the USA which is lower
compared to EU and AU. Furthermore, due to geographic
distances within the USA, the period of follow-up was
frequently shorter. Although we found no significant dif-
ferences in resolution rates between patients that did or did
not undergo confirmatory testing and between the different
follow-up periods, we cannot exclude that this has influ-
enced the outcomes.
Similar to most studies regarding PA, the need for a
retrospective design, due to the low prevalence of PA, is
one of the weaknesses of our study. This made it impos-
sible to use standardized measurement procedures for
clinical outcomes such as blood pressure measurements.
Although the duration of follow-up had no significant
influence on resolution of hypertension rates, the short
period of follow-up in a substantial number of patients
could also be a potential weakness of this study. Also, the
limited number of participating medical centers from CA
and AU, resulting in relatively wide confidence intervals of
the AUC, should be taken into account.
As presented in earlier studies, the distribution of reso-
lution rates might differ across countries or continents,
which also was the case in our study [13–16]. In line,
predictors for a certain outcome might differ between
geographic populations and the effect or magnitude of
predictors might change over time. Although dichotomous
variables, as used within the ARS, simplify the use of
prediction models in daily clinical practice, much infor-
mation within the data is lost. This was best illustrated by
the significant higher mean BMI within the USA, com-
pared to the other three geographic regions, which did not
lead to fewer patients with BMI B 25 kg/m2 and a lower
ARS. Moreover, the cutoffs for dichotomized variables are
often driven by the data, hampering the generalizability of
prediction models [20–22]. Therefore, in future studies, a
prediction model ideally should include continuous instead
of dichotomous variables. Moreover, in a world of rising
technology and easy access to electronic devices and web-
based applications, a prediction model containing contin-
ues variables could be user-friendly as well.
Conclusion
The ARS is a user-friendly prediction model for clinicians
during patient counseling with a moderate to good pre-
dictive performance within current clinical practice. The
model showed the highest predictive performance within
North America, but potentially has less predictive perfor-
mance in EU and AU indicating the potential limited
generalizability outside of the North American APA
population.
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